CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer.

Jiachen XuanRichard B PearsonElaine Sanij

Published in: Molecular & cellular oncology (2020)

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.

Keyphrases

high grade
low grade
dna damage
dna repair
big data
emergency department
machine learning
adverse drug
data analysis